Baiyunshan: after the approval of the imitation Viagra tablet, the API is under review

Source: on the evening of July 31, 2014, Baiyunshan (600332), on August 1, 2014, issued a Clarification Announcement on the website of securities times The company paid attention to the media reports that the company imitated "Viagra" to be listed According to the company, upon inquiry of the website of CFDA administrative acceptance service center of the State Food and drug administration, the "processing status" of the application for production registration approval of sildenafil citrate (Viagra) tablet submitted by the company has been updated to "approval completed pending certification" at 9:08 on July 30, 2014 According to the description of CFDA administrative Acceptance Center website, "approval completed - Certificate to be prepared" means that CFDA administrative acceptance service center is making approval documents Upon inquiry, the "processing status" of the application for "sildenafil citrate" API production registration approval submitted by the company has been updated to "under approval" at 14:31 on June 9, 2014 According to the CFDA administrative Acceptance Center's website, "in approval" refers to the approval in the State Food and drug administration Previously, Baiyunshan obtained the new drug certificate of "sildenafil citrate" API and tablet in 2003 Baiyunshan said that the company has the "Jinge" trademark with the approved registration numbers of "No 1533743", "No 4894150" and "No 4894151", which is approved for the use of human drugs, medical preparations, chemical pharmaceutical preparations, APIs and other commodities After obtaining the production registration approval of APIs and tablets, the company will promote relevant work as soon as possible, and realize the production and marketing of "sildenafil citrate" products with the trade name of "Jinge" as soon as possible.